123 related articles for article (PubMed ID: 18220734)
1. Towards the development of a broadly protective group a streptococcal vaccine based on the Lipid-Core Peptide system.
Olive C; Moyle PM; Toth I
Curr Med Chem; 2007; 14(28):2976-88. PubMed ID: 18220734
[TBL] [Abstract][Full Text] [Related]
2. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
Moyle PM; Olive C; Ho MF; Good MF; Toth I
J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
5. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
6. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
7. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
9. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
10. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
11. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
Moyle PM; Olive C; Good MF; Toth I
J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
16. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
17. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
20. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]